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Abstract
Background: Controversies exist as to whether the genetic polymorphisms of the enzymes responsible for the
metabolism of tamoxifen can predict breast cancer outcome in patients using adjuvant tamoxifen. Direct
measurement of concentrations of active tamoxifen metabolites in serum may be a more biological plausible and
robust approach. We have investigated the association between CYP2D6 genotypes, serum concentrations of active
tamoxifen metabolites, and long-term outcome in tamoxifen treated breast cancer patients.
Methods: From an original observational study comprising 817 breast cancer patients, 99 women with operable breast
cancer were retrospectively included in the present study. This cohort of patients were adjuvantly treated with tamoxifen,
had provided serum samples suitable for measuring tamoxifen metabolites, and were relapse-free at 3 years after the
primary treatment commenced. The median follow-up time from this entry point to breast cancer death was 13.9 years.
Patients were CYP2D6 genotyped and grouped into four CYP2D6 phenotype groups (Ultra rapid, extensive, intermediate,
and poor metabolizers). Tamoxifen and nine metabolites were quantified in serum (n = 86) and compared with CYP2D6
phenotype groups and outcome.
Results: Breast cancer patients with low concentrations of Z-4-hydroxy-tamoxifen (Z-4OHtam; ≤ 3.26 nM) had a breast
cancer-specific survival (BCSS) of 60% compared to 84% in patients with Z-4OHtam concentrations > 3.26 nM (p = 0.020,
log-rank hazard ratio (HR) = 3.56, 95% confidence interval (CI) = 1.14–11.07). For patients with Z-4-hydroxy-N-desmethyl-
tamoxifen (Z-endoxifen) levels≤ 9.00 nM BCSS was 57% compared to 84% for patients with concentrations > 9.00 nM
(p = 0.029, HR = 3.73, 95% CI = 1.05–13.22). Low concentrations of Z-4OHtam and Z-endoxifen were associated with
poorer survival also after adjusting for clinically relevant variables (HR = 4.27, 95% CI = 1.35–13.58, and HR = 3.70, 95%
CI = 1.03–13.25, respectively). Overall survival analysis showed similar survival differences for both active metabolites. The
Antiestrogen Activity Score showed comparable effects, but did not improve the prognostic information.
Conclusions: Patients with Z-4OHtam and Z-endoxifen concentrations lower than 3.26 nM or 9.00 nM, respectively,
showed an adverse outcome. Our results suggest that direct measurement of active tamoxifen metabolite
concentrations could be of clinical value. Validation in larger study cohorts is warranted.
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Background
Tamoxifen is a selective estrogen receptor modulator used
for adjuvant treatment of luminal (estrogen receptor (ER)-
positive and/or progesterone receptor (PR)-positive) breast
cancer (BC) subtypes. Tamoxifen is the oldest and most
prescribed endocrine BC drug and has been shown to re-
duce BC mortality by 31% [1] and BC recurrence by 50%
[2]. Tamoxifen is a widely used endocrine adjuvant treat-
ment option among pre-menopausal BC patients, with
therapy durations of up to 10 years [3, 4]. Post-menopausal
BC patients are mainly given aromatase inhibitors (AIs) for
5 years, in combination with tamoxifen for a 3–5 year
period, or tamoxifen monotherapy for 10 years if the side
effects from AIs are too bothersome [5]. Hence, tamoxifen
is still an important drug in the management of BC. How-
ever, interpatient variability in the anti-ER response and ad-
verse effects are common. Within 15 years of primary
surgery one-third of BC patients receiving tamoxifen will
have relapsed [1].
The interpatient variability in the clinical response to
tamoxifen has been suggested to be connected to its en-
zymatic conversion into active metabolites. Several of
these activating enzymes are polymorphic, including
cytochrome P450 2D6 (CYP2D6), as combinations of
the CYP2D6 alleles have been related to various kinetic
activity levels of the enzyme. CYP2D6 is a key enzyme
in the formation of the two active metabolites, Z-4-
hydroxy-N-desmethyl-tamoxifen (Z-4OHNDtam, also
known as Z-endoxifen) and Z-4-hydroxy-tamoxifen (Z-
4OHtam) [6], and concentrations of these two active
metabolites have been found to be associated with
CYP2D6 genotypes [7, 8]. Z-endoxifen and Z-4OHtam
are 30- to100-fold more potent anti-ER inhibitors than
the mother drug tamoxifen [9]. Endoxifen is present at up
to 10 times higher plasma concentrations than 4OHtam
and is therefore regarded as the most powerful metabolite
[6]. After Goetz et al. in 2005 reported an association be-
tween the CYP2D6 poor metabolizer (PM) phenotype and
higher risk of relapse among tamoxifen users [10], several
reports have been published on CYP2D6 genotype and out-
come. However, the various studies have reported contra-
dictory results and more knowledge is required in order to
make any conclusions [11–14].
An alternative approach would be to measure the con-
centrations of the active metabolites directly in serum
and associate them with breast cancer outcomes. As the
active metabolites are strong ER ligands, their serum
levels may better reflect the functional anti-estrogenic
effects in patients treated with tamoxifen. Recently,
methods to separate the Z-isomers (Z-endoxifen and Z-
4OHtam) from the less active or inactive isomers have
been developed [15]. The additive anti-ER effect from
tamoxifen metabolites and isomers with various affinity
to the ER may also be of importance to estimate the
resultant effect of tamoxifen itself and all active tamoxi-
fen metabolites [16].
In the present study, we have determined the CYP2D6
genotypes and serum concentrations of tamoxifen and
nine metabolites in 99 BC patients with a long-term
follow-up. Our aim was to investigate the predictive
value of direct measurements of active serum tamoxifen
metabolites in patients with operable breast cancers and
to compare these results with the CYP2D6 genotyping
method. We hypothesized that the genotype approach is
inferior to direct measurement of tamoxifen metabolites
regarding prediction of prognosis, and that patients with
low serum levels of active tamoxifen metabolites will
have poorer prognosis.
Methods
In this retrospective observational study the primary ob-
jective was to compare the prognostic value of direct
measurements of tamoxifen metabolites in serum with
CYP2D6 genotyping in 99 operable breast cancer pa-
tients. The secondary objective was to investigate the as-
sociations between concentrations of active tamoxifen
metabolites and CYP2D6 phenotypes.
Patients
Between May 1995 and December 1998, 817 patients
were studied in a population-based observational
micro-metastasis study [17] in Oslo, Norway. The pa-
tients were treated according to the national guide-
lines at the time. All patients with hormone receptor-
positive tumors received 20 mg tamoxifen daily for
5 years. The tumor was defined as hormone receptor
positive if ≥ 10% of the cells were positive for ER or
PR by immunohistochemistry analysis.
From this original study population, serum was drawn
from 356 relapse-free patients 3 years after inclusion. Of
these, 99 operable BC patients comprising T1/T2 tu-
mors were adjuvantly treated with tamoxifen and in-
cluded in the present study. The demographic and
clinical characteristics are presented in Table 1. The me-
dian follow-up time for breast cancer death from this
entry time was 13.9 years (range 0.6–16.5 years). The
present study population of 99 patients did not differ
from the relapse-free cohort [17] with regard to clinical
and tumor biological variables other than the treatment
selection (Table 1).
CYP2D6 genotyping and classification of CYP2D6
phenotype groups
DNA was isolated from the blood or bone marrow using
the Gentra Puregene Blood kit (Qiagen, Hilden, Germany)
or an automated phenol-chloroform procedure. The
CYP2D6 genotype determination was performed at the
Expert Center for Pharmacogenetics, Department of
Helland et al. Breast Cancer Research  (2017) 19:125 Page 2 of 13
Clinical Chemistry, Erasmus University Medical Center,
Rotterdam, The Netherlands, using the CE-IVD approved
INFINITI® CYP450 2D6I Assay (Autogenomics, Carlsbad,
CA, USA) and verified using the Taqman DME assay
(Thermo Fisher Scientific, Waltham, MA, USA) according
to validated standard operating procedures in an
ISO15189-certified laboratory. INFINITI detects 15 vari-
ant alleles (Additional file 1: Table S1) and the CYP2D6
genotypes of the patients were determined based on the
combination of wild-type (wt) and variant-type (vt) alleles
and translated into four predicted CYP2D6 phenotype
groups: ultra-rapid metabolizers (UM; gene duplication
positive, no inactive variants), extensive/normal metaboli-
zers (EM; no variants or only one decreased activity allele),
intermediate metabolizers (IM; two decreased activity al-
leles or one active and one inactive allele), and poor meta-
bolizers (PM; two inactive alleles).
Determination of tamoxifen metabolites by liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
We developed a LC-MS/MS method to quantify tamoxi-
fen and nine of its metabolites in human serum. All me-
tabolites and four de uterated internal standards were
obtained commercially (Additional file 2: Table S2).
Table 1 Patient demographics and characteristics
Characteristics Present study
population
(n = 99)
Relapse free
at 3 years
(n = 356)
Differences between
the groups
(P values)
Age at diagnosis (years)
Mean (median) 58 (56) 57 (56)
Range 34–78 28–85 0.380
Menopause status, n (%)
Pre (< 55 years) 40 (40%) 151 (42%)
Post (≥ 55 years) 59 (60%) 205 (58%) 0.710
Histology, n (%)
IDC 74 (75%) 251 (76%) 0.109
ILC 24 (24%) 69 (19%)
Other infiltrating cancer 1 (1%) 16 (5%)
Tumor size, n (%)
pT1 50 (51%) 253 (71%) < 0.001*
pT2 49 (49%) 87 (25%)
pT3 – 12 (3%)
pT4 – 0 (0%)
pTx – 3 (1%)
Tumor grade, n (%)
G1 18 (18%) 110 (31%) 0.009
G2 67 (68%) 184 (52%)
G3 12 (12%) 56 (15%)
Not reported 2 (2%) 6 (2%)
Node status, n (%)
Positive 57 (58%) 93 (71%) < 0.001
Negative 41 (41%) 257 (27%)
Not reported 1 (1%) 6 (2%)
HER2/neu status, n (%)
HER2+ 7 (7%) 36 (10%) 0.193
HER2– 89 (90%) 298 (84%)
Unknown 3 (3%) 22 (6%)
Comparison of the demographic and clinical characteristics between the patients in the present study population and 356 relapse-free patients from the original
population [17]
The present study population comprises more patients with pT2 tumors, higher grade, and node-positive status due to treatment selection
*The present study population only included operable breast cancer patients; therefore p value of tumor size comparison is between pT1 and pT2 populations
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, pT pathological tumor size
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Calibrators were created from pooled human serum of
three male and six female non-tamoxifen users to which
tamoxifen metabolites were added at seven concentra-
tions (Additional file 3: Table S3).
Serum samples (50 μl) containing tamoxifen metabo-
lites were processed using a Hamilton STAR pipetting
robot (Bonaduz, Switzerland). Serum proteins were pre-
cipitated by adding 500 μL acetonitrile containing in-
ternal standards to the samples; 350 μL of the
supernatant was evaporated to dryness under a nitrogen
flow and subsequently reconstituted in 500 μL methanol
and diluted 1 to 25 in water:methanol (20:80, v:v) before
being subjected to LC-MS/MS analysis.
An Aquity UPLC system from Waters (MA, USA) with
a thermostated column oven set at 50 °C was used to
chromatographically separate the compounds; 25 μL of
sample was injected onto a 100-mm BEH Phenyl column
with a 2.1 mm internal diameter and 1.7 μm particle size
(Waters, Milford, MA, USA). The column was developed
by a weak mobile phase (A) consisting of water, and a
strong mobile phase (B) consisting of methanol, both buff-
ered with 0.01% formic acid. All gradient steps were linear,
and the flow rate was 300 μL/min. The following gradient
was used: 0–0.5 min: 95% A and 5% B; 1 min: 65% A and
35% B; 4 min: 10% A and 90% B; 4.5–8 min: 100% B; 8.1–
9 min: 90% A and 10% B.
The LC system was coupled to a Xevo TQ-S tandem
mass spectrometer (Waters, Milford, MA, USA)
equipped with an atmospheric pressure photoionization
source (APPI). All compounds were analyzed in the
positive mode. Additional file 4: Table S4 shows reten-
tion times and compound-dependent settings for the
tamoxifen metabolites.
Validation of the LC-MS/MS method
The selectivity of the method is demonstrated in Fig. 1 as
it separated the active Z-isomers of 4OHtam and endoxi-
fen from its less active Z’-isomers and inactive E-isomers.
Total analytical run-time was 9 min and the sample vol-
ume of serum was 50 μL. Accuracy and imprecision was
well within the acceptance criteria defined by regulatory
guidelines (Food and Drug Administration (FDA), Rock-
ville, MD, USA; 2002). The method was linear for all ana-
lytes (Additional file 5: Table S5). For medium
concentrations, imprecision (intra- and inter-day CV %)
was within 9% and accuracies were in the range 95–106%
(Additional file 3: Table S3) for all metabolites except cis-
β-OHtam and z-α-OHtam, which had imprecision within
15% accuracies in the range 87–109%. Cis-β-OHtam and
z-α-OHtam were not detected in patient samples.
Data analyses and statistics
SPSS statistical software, version 23 (SPSS, Inc., Chicago,
IL, USA), and MedCalc for Windows, version 16.4.3
(MedCalc Software, Ostend, Belgium), were used for the
basic statistical calculations.
Supervised cut-off values for Z-endoxifen (9.00 nM),
Z-4OHtam (3.26 nM), and Antiestrogenic Activity Score
(AAS) (16.7) were identified by multivariable Cox ap-
proach as described in Additional file 6.
Fig. 1 MRM transitions of tamoxifen and its metabolites. The chromatograms are obtained by analyzing the second point of the calibration curve.
The chromatographic separation of isomers of 4OHtam and endoxifen are shown in the lowest and second lowest panels, respectively. APPI atmospheric
pressure photoionization, MRM multiple reaction monitoring
Helland et al. Breast Cancer Research  (2017) 19:125 Page 4 of 13
The present study included patients that had survived
the first three 3 years after surgery without experiencing
any relapse. The analysis is thus conditional on 3 year
relapse-free survival, and in the survival analysis 3 years
after surgery is used as the time origin to partially ad-
dress the pitfall of immortal person time bias [18–20].
Breast cancer-specific survival (BCSS) was defined as the
time from the primary surgery until death from breast
cancer. Cause of death was provided from the hospital
records, and in a few cases also by information from the
patient's general physician.
Survival estimates were calculated by the Kaplan-Meier
method. Univariable tests for survival differences in cat-
egorical variables were performed by the log-rank test or
the log-rank test for trend as appropriate. Multivariable
regression analysis for clinically relevant variables was per-
formed using the Cox proportional hazards method. Chi-
square, Mann-Whitney U test or Kruskal-Wallis were
used for comparisons between groups as needed. Fisher’s
exact test was used when appropriate. Two-tailed P values
< 0.05 were considered statistically significant.
To estimate the resultant ER blockade of tamoxifen
itself and the various active tamoxifen metabolites we
used the AAS as previously described [16]. In short,
the estimation of the AAS was based on the serum
concentrations of the various active tamoxifen
metabolites and their relative affinity to the ER by the
following algorithm: 0.01 × [Tamoxifen] + 1 × [Z-endox-
ifen + Z-4OHtam] + 0.1 × [Z′-endoxifen + Z′-4OHtam].
Results
CYP2D6 genotyping and quantification of tamoxifen
metabolites in serum
CYP2D6 allele frequencies are shown in Additional file
7: Table S6 and the most frequent genetic variants *1, *2,
*4 and *41 were in Hardy-Weinberg equilibrium (HWE).
The frequency of the remaining 5 alleles (*3, *5, *6, *9,
and *10) were too rare in our study cohort to perform a
HWE calculation. Ninety-one patients were successfully
CYP2D6 genotyped and the phenotypes were distributed
as follows: 4 (4.4%) ultra-rapid metabolizers, 43 (47.3%)
extensive/normal metabolizers, 36 (39.6%) intermediate
metabolizers, and 8 (8.8%) poor metabolizers. Eight pa-
tients were excluded from CYPD6 analysis due to inad-
equate volumes of blood/bone marrow for DNA
extraction or because of poor quality of DNA.
Concentrations of tamoxifen and nine metabolites
were measured using LC-MS/MS. All patient serum
samples were run in duplicate (Table 2). The mean and
median concentrations of tamoxifen and the nine me-
tabolites for the 86 patients are shown in Table 2. Cis-β-
OHtam and z-α-OHtam were included for separation of
the hydroxylated metabolites [21] and were not detect-
able in patient samples. As shown before [22], large
inter-individual variations in the concentrations of tam-
oxifen metabolites were observed between patients
(Table 2). Thirteen patients had concentrations below
the lower limits of quantification (LLQ) for tamoxifen
and all the nine metabolites. These patients were
regarded as non-adherent and excluded from the present
study, leaving 86 patients for further analyses.
Associations between CYP2D6 phenotype groups and
concentrations of tamoxifen metabolites
The median values for all metabolite concentrations
stratified by CYP2D6 phenotype groups are shown in
Additional file 8: Table S7. An association between de-
clining concentration levels and decreased CYP2D6
function was observed for Z-4OHtam and Z-endoxifen
(p = 0.05 and p < 0.001, respectively; Kruskal-Wallis)
(Fig. 2). Notably, there is a wide spread of levels of active
metabolites within each CYP2D6 phenotype group and
also a considerable overlap between them; for example,
use of the 3.26 nM (red line) and 8.13 nM (green line)
cut-off values for Z-4OHtam will include patients from
three CYP2D6 phenotype groups (Fig. 2). None of the
other metabolite concentrations showed an association
with CYP2D6 phenotype.
Breast cancer outcome in association with CYP2D6
phenotype and active tamoxifen metabolite
concentrations
To investigate the association between CYP2D6 pheno-
type and survival, a Kaplan-Meier linear trend analysis
comparing the survival of the four CYP2D6 phenotype
groups (UM, EM, IM, and PM) was performed (Fig. 3).
No significant association was observed (p = 0.966, total
log-rank). However, using EM as a reference we
achieved 80% power to detect hazard ratios (HRs) of 3.3,
10, and 35 for IM, PM, and UM, respectively. Therefore,
the result should be interpreted with care. Notably, the
excluded non-adherent patients (n = 13) were evenly dis-
tributed among the various CYP2D6 phenotype groups,
and including them did not change the results.
A Cox log-linear trend analysis controlling for age,
tumor size, grade, node status, ER, PR, and chemotherapy
was performed to investigate the association between con-
centrations of tamoxifen metabolites and outcome. We
identified a log-linear relationship between Z-4OHtam
and BCSS (p = 0.044, HR = 0.75, 95% confidence interval
(CI) = 0.56–0.99), indicating a 0.25 reduction in hazard for
each unit (1 nM) increase in Z-4OHtam. There was no
log-linear association between Z-endoxifen or the
remaining metabolites and breast cancer outcome. We
further wanted to explore the possibility of an association
between survival and concentration thresholds for the
active metabolites Z-4OHtam and Z-endoxifen. We
identified supervised cut-off values representing low
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concentrations for Z-4OHtam (3.26 nM) and Z-endoxifen
(9.00 nM) as described in the Methods section and per-
formed univariable survival analyses (Fig. 4a and b). For
Z-4OHtam the BCSS was 60% vs. 84% for the ≤ 3.26 nM
and > 3.26 nM groups, respectively (p = 0.020; log-rank
HR = 3.56, 95% CI = 1.14–11.07). For Z-endoxifen we
observed a BCSS of 57% vs. 84% for the ≤ 9.00 nM and >
9.00 nM groups, respectively (p = 0.029; log-rank HR =
3.73, 95% CI = 1.05–13.22). Adjustment for age, tumor
size, nodal status, histological grade, ER and PR status,
and chemotherapy given left Z-4OH tam and Z-endoxifen
as the only factors in the final models with HR = 4.27
(95% CI = 1.35–13.58) and HR = 3.70 (95% CI = 1.03–
13.25), respectively.
The Z’ isomers of the active metabolites also have
anti-estrogenic activity and, since our LC-MS/MS was
able to measure the Z and Z’ isomers of 4OHtam and
endoxifen separately, we were able to calculate the AAS
score (as described in Additional file 6). We further
identified threshold values representing patients with
low and high AAS and showed a BCSS of 57% for pa-
tients with AAS ≤ 16.7 compared to 84% in patients with
ASS > 16.7 (p = 0.026, HR = 3.81, 95% CI = 1.07–13.56)
(Additional file 9: Figure S1). Adjusting for the same
variables as mentioned above, AAS was the only factor
associated with BCSS (p = 0.041, HR = 3.80, 95% CI =
1.06–13.64). We also investigated the possible effect on
outcome from tamoxifen itself, the two Z’-isomers alone,
Table 2 Concentrations of tamoxifen and nine metabolites in 86 breast cancer patients
Analyte Mean (median)
serum concentration (nM)
Analytical
CV %
Interpatient variability
CV %
Tamoxifen 322.2 (287.5) 6.61 45.46
NDtam 723.2 (689.0) 9.55 44.75
Z-4OHNDtam 30.11 (28.15) 6.46 59.01
4'OHNDtam 30.08 (28.13) 8.18 38.09
Z-4OHtam 5.67 (5.30) 6.03 42.32
4'OHtam 7.64 (7.20) 7.54 39.34
Tam-N-ox 119.6 (97.52) 11.04 60.12
NNDDtam 92.69 (81.17) 11.14 50.80
cis-β-OHtam ND – –
z-α-OHtam ND – –
Samples were run in duplicate
Thirteen patients with metabolite levels below the limit of detection are not included in the calculations, leaving 86 patients for further analysis
Analytical CV % indicates average CV between two replicate samples for all patients
CV coefficient of variation, ND not detected
Fig. 2 Z4OHtam and Z-endoxifen concentrations compared by CYP2D6 phenotype groups. Impaired CYP2D6 function correlates with lower levels
of Z-4OHtam and Z-endoxifen (p = 0.05 and p <0.001, respectively; Kruskal-Wallis). Cut-off values representing patients with high levels (green line)
and low levels (red line) of active metabolites are shown. EM extensive metabolizer, IM intermediate metabolizer, PM poor metabolizer,
UM ultra-rapid metabolizer
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and the various non-active metabolites. No significant
thresholds were identified.
In the analysis for overall survival (OS), Z-4OHtam, Z-
endoxifen, and AAS were all significant in the univari-
able analysis (Table 3). When adjusting for the various
clinico-pathological variables, tumor size, nodal status,
and chemotherapy were added to the final models
(Table 4).
The significant linear trend observed for Z-4OHtam
encouraged us to also assess survival effects for very
high levels of active metabolites. We therefore arbi-
trarily used the concentrations corresponding to the
median concentrations for Z-4OHtam and Z-
endoxifen ultra-rapid metabolizers (UM) as cut-off
values, i.e., 8.13 nM and 59.59 nM, respectively
(Fig. 2). Hence, patients were re-grouped into low,
intermediate, and high serum concentrations of Z-
4OHtam and Z-endoxifen, respectively (Fig. 4c and d).
The Kaplan-Meier log-rank trend test demonstrated
significant survival differences between these three sub-
groups for both metabolites (Z-4OHtam, p = 0.010; Z-
endoxifen, p = 0.026) with no BCSS events for patients
with high concentrations of active metabolites (Fig. 4c
and d). The same differences were also observed in
the overall survival analysis (Z-4OHtam, p = 0.002; Z-
endoxifen, p = 0.014; log-rank trend) (Fig. 4e and f ).
Notably, the distribution of all the adjusted clinic-
pathological variables were equal between the low and
the high serum concentration subgroups.
Discussion
In the present study we identified an association be-
tween CYP2D6 phenotype groups and the serum levels
of active metabolites (Z-4OHtam and Z-endoxifen).
However, we did not find an association between
CYP2D6 phenotypes and breast cancer outcome (Fig. 3).
The low power to detect a relevant survival difference
between the CYP2D6 phenotype groups (i.e., HR be-
tween 1.5 and 2.5) is a possible explanation for its absent
prognostic value in the present study. We further inves-
tigated the association between concentrations of active
metabolites and breast cancer outcome, and this is to
our knowledge the first study to report a relationship
between low levels of the active tamoxifen metabolites
and higher risk of breast cancer death (Fig. 4). The
long follow-up time in our study allowed the use of
breast cancer-specific survival as the clinical endpoint.
We identified threshold values representing low and
high levels of active metabolites. Notably, these cut-
off values included patients from all CYP2D6 pheno-
type groups suggesting that the genotype approach
results in grouping of patients with heterogeneous
serum levels of active metabolites (Fig. 2).
To our knowledge, only three studies have analyzed
the association between tamoxifen metabolite concentra-
tions and relapse of breast cancer [23–25]. Madlensky et
al. found a 30% higher risk of relapse in patients with
low endoxifen levels (<16 nM) in patients grouped ac-
cording to endoxifen quintiles [23]. In a recent study, a
higher risk of distant relapse was observed in patients
with low (<14.15 nM) vs high (>35 nM) Z-endoxifen
levels when splitting the patients into endoxifen quar-
tiles [24]. Both studies reported that the lowest quintile/
quartile had the worst outcome, whereas the highest
quintile/quartile had the best outcome. Thus, it seems
that the use of active metabolite thresholds creates re-
producible results in survival analyses probably due to
grouping of patients that are homogeneous regarding
the anti-ER effect. This is in line with our results since
we also observed a favorable survival in breast cancer
patients with high serum metabolite levels. Our high
cut-off value is equal to the median concentrations of
active metabolites in the UM group (Fig. 2), and other
studies have shown that UM groups are often reported
to be in the best prognostic range in the subgroup ana-
lyses [26]. In a third study, no association was found be-
tween endoxifen levels and breast cancer outcome in
patients receiving low doses of tamoxifen (1 mg, 5 mg,
and 10 mg) [25]. However, the authors speculate that
sensitivity issues for detecting differences at very low
concentrations may have clouded the results. In
addition, preliminary results presented at ASCO 2016
[27] showed no association between endoxifen concen-
trations and BC outcome. However, this study included
Fig. 3 Kaplan-Meier plot of BCSS for CYP2D6 phenotypes. Patients
are grouped according to CYP2D6 phenotype group as indicated by
the colored lines. Time starting at 3 years after surgery. EM extensive
metabolizer, IM intermediate metabolizer, PM poor metabolizer, UM
ultra-rapid metabolizer
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patients receiving 20 mg tamoxifen in the metastatic
setting or as neoadjuvant treatment, a very different
context often with developed endocrine resistance.
Hence, this patient group is difficult to compare with
the operable patients undergoing adjuvant tamoxifen
treatment in our study. Interestingly, in a phase I
study administering oral Z-endoxifen 160 mg daily in
endocrine refractory metastatic breast cancer patients
[28] the response rate on the tumor was 26% and the
side effects were tolerable, with endoxifen concentra-
tions up to 5200 nM maintained over 28 days. This
study suggests that the concentrations of the active
metabolites may be important for the apoptotic effect
on breast cancer cells [28].
Fig. 4 Kaplan-Meier plots of BCSS and overall survival for concentrations of active tamoxifen metabolites. Patients are grouped according
to concentrations of active metabolites as indicated by colored lines. Time starting at 3 years after surgery. a,b BCSS for Z-4OHtam and
Z-endoxifen at concentrations above and below 3.26 nM and 9.00 nM, respectively. c,d BCSS for Z-4OHtam and Z-endoxifen at three
serum concentrations: low, intermediate, and high levels, as shown in the figure. e,f Overall survival for Z-4OHtam and Z-endoxifen at the
same three concentrations as shown in c and d. HR hazard ratio
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Here, we report for the first time an association be-
tween Z-4OHtam and BC outcome. Although endoxifen
is present at higher serum concentrations than Z-
4OHtam, their affinity to the ER is the same. Cross
tabulation between Z-endoxifen (cut-off 9.0 nM) and Z-
4OHtam (cut-off 3.26nM) shows that 50% of patients
below the Z-4OHtam threshold were not identified by
the Z-endoxifen threshold (Additional file 10: Table S8).
This implies that measuring Z-4OHtam may be of clin-
ical value. The Z’-isomers of the active metabolites also
have a certain antiestrogenic effect. After calculation of
tamoxifen and all active metabolites by means of the
AAS score, we observed a significant association be-
tween low AAS score and worse BCSS (Additional file 9:
Figure S1). However, using the AAS score was not su-
perior to the use of Z-endoxifen and Z-4OHtam
Table 3 Univariable survival analyses of breast cancer-specific survival and overall survival
Breast cancer-specific survival Overall survival
Factor Event/at risk HR 95% CI P Event/at risk HR 95% CI P
Tumor size
pT1 7/44 1 11/44 1
pT2 9/42 1.47 0.55–3.96 0.439 16/42 1.70 0.79–3.67 0.169
Node status
pN0 4/33 1 9/33 1
pN+ 12/52 2.00 0.64 –6.19 0.222 18/52 1.33 0.60–2.96 0.484
Histological grade
1 3/16 1 6/16 1
2 10/57 0.94 0.26–3.42 0.924 16/57 0.76 0.30–1.94 0.564
3 3/11 1.48 0.30–7.35 0.631 5/11 1.30 0.40–4.28 0.661
Histological grade
1 + 2 13/73 1 22/73 1
3 3/11 1.56 0.44–5.46 0.335 5/11 1.61 0.61–4.25 0.335
Age
< 55 years 7/35 1 7/35 1
≥ 55 years 9/51 0.93 0.35–2.51 0.890 20/51 2.09 0.89–4.95 0.085
ER
≥ 10% 15/75 1 26/75 1
< 10% 1/7 0.63 0.08–4.73 0.646 1/7 0.36 0.05–2.65 0.294
PR
≥ 10% 11/55 1 17/55 1
< 10% 4/27 0.72 0.23–2.25 0.566 9/27 0.98 0.43–2.19 0.951
Chemotherapy*
Yes 6/30 1 6/30 1
No 10/56 0.93 0.34–2.57 0.893 21/56 1.97 0.80–4.89 0.135
AAS
> 16.7 13/79 1 21/79 1
≤ 16.7 3/7 3.81 1.07–13.56 0.026 6/7 5.37 2.14–13.51 < 0.001
Z-4OHtam
> 3.26 nM 12/76 1 20/76 1
≤ 3.26 nM 4/10 3.56 1.14–11.11 0.020 7/10 4.05 1.70–9.64 0.001
Z-endoxifen
> 9.00 nM 13/79 1 22/79 1
≤ 9.00 nM 3/7 3.73 1.05–13.23 0.029 5/7 4.03 1.51–10.74 0.003
* Did the patients receive chemotherapy according to the treatment guidelines at the time
AAS antiestrogenic activity score, CI confidence interval, ER estrogen receptor, HR hazard ratio, pN pathologic node status, PR progesterone receptor, pT pathologic
tumor size
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concentrations, strengthening previous observations that
Z-endoxifen and Z-4OHtam are the most active tamoxi-
fen metabolites. In line with our results, a recent study
showed an aggregate effect of tamoxifen and three me-
tabolites on breast cancer relapse [29] without providing
additional prognostic information compared to the use
of endoxifen levels alone.
Our supervised threshold for low concentrations of
endoxifen identified in the present study (9.00 nM) is
slightly lower compared to the un-supervised thresh-
olds identified in previous studies (16 nM and 14.15
nM) [23, 24]. Using these cut-off values in the
present study, we observed the same pattern with
poorer survival for the lower concentration groups;
however, significance was not reached. Thresholds will
vary depending on the number of patients included in
a study, the statistical methods to determine cut-off
values [30], the underlying patient distribution [31],
and the assay used to quantify the metabolites.
Moreover, the threshold of a single metabolite in a
clinical study (in-vivo setting) may be influenced by
the relative concentrations of all the other metabolites
present in the same environment. Thus, they will
compete on the same binding site of the ER and con-
tribute to the numeric difference in cut-off values.
Intriguingly, all the above three cut-off values identify
a clinical relevant patient group with poor outcome in
the lower concentration extremities of Z-endoxifen and
Z-4OHtam. Admittedly, our supervised thresholds may
also have inflated the P values [32] and exaggerated the
survival differences between subgroups in the present
study. Hence, the threshold values in this learning set
must be interpreted with caution and validation of the
thresholds in a larger independent material is warranted
[33]. Importantly, consensus on the “correct clinical
threshold” should aim to characterize patients with low
benefit of tamoxifen with a certain safety margin to
avoid under-treatment.
Table 4 Overall survival; multivariable analysis including Z-4OHtam, Z-endoxifen, and AAS
Continuous variables Categorical variables
Factor HR per unit* 95% CI P Factor HR 95% CI P
Z-4OHtam Z-4OHtam > 3.26 nM 1
Adjusted† 0.81 0.66–0.99 0.040 ≤ 3.26 nM 4.86 1.88–12.54 0.001
Unadjusted 0.85 0.70–1.02 0.077 pT 1 1
2 2.59 1.11–6.05 0.028
pN Negative 1
Positive 2.89 1.12–7.49 0.029
Chemotherapy Yes 1
No 2.34 0.90– 6.11 0.083
Z-endoxifen Z–endoxifen > 9.00 nM 1
Adjusted† 0.99 0.96–1.02 0.365 ≤ 9.00 nM 5.65 2.00–16.00 0.001
Unadjusted 0.99 0.97–1.02 0.580 pT 1 1
2 2.44 1.08–5.49 0.032
pN Negative 1
Positive 2.40 0.99–5.80 0.052
Chemotherapy Yes 1
No 3.41 1.24–9.39 0.017
AAS AAS > 16.7 1
Adjusted† 0.99 0.97–1.01 0.313 ≤ 16.7 8.39 2.90–24.26 <0.001
Unadjusted 0.99 0.98–1.10 0.532 pT 1 1
2 2.60 1.15–5.91 0.022
pN Negative 1
Positive 3.40 1.26–9.15 0.016
Chemotherapy Yes 1
No 2.67 1.03–6.94 0.044
* Change in hazard ratio (HR) per 1 nM increase in serum concentration of Z-4OHtam, Z-endoxifen, change in HR per 1 unit Antiestrogenic Activity Score
(AAS; dimensionless)
† Adjusting variables: pT, pN, histological grade, estrogen receptor, progesterone receptor, age, and chemotherapy
CI confidence interval, pN pathologic node status, pT pathologic tumor size
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There are some limitations to the present study. First,
our patient population of 86 patients is small. Despite
the low number of patients, we were able to identify sig-
nificant associations between Z-4OH tam and Z-
endoxifen levels and outcome probably due to our long
follow-up time (median 13.8 years). The low number of
events in each subgroup calls for caution in interpreting
the results and may explain the lack of statistical power
to determine prognostic information from the CYP2D6
phenotype groups. Therefore, validation in larger study
cohorts is warranted. Furthermore, information on long-
term adherence (5 years) and co-medication, such as
CYP2D6 inhibitors, would have strengthened our study.
Entry of patients after a 3-year relapse-free period post-
surgery has created loss of early endpoints occurring
during the first 3 years of follow-up. This might have con-
tributed to the observed loss of prognostic information of
the proliferation-related variables such as pT, pN, and
histological grade in these luminal breast cancer subtypes.
This selection bias will favor patients with late events in
the natural course of their disease. In patients with
luminal breast cancers, approximately 75% of the breast
cancer-related deaths occur after 3 years [34]. As the
present study comprises only patients with this tumor
type with a long-term follow-up (i.e., up to 16.5 years) we
believe that our findings are of value for evaluating the 3-
year conditional survival in this patient group.
Conclusions
Although tamoxifen has been on the market for several
decades and is the most used drug against breast cancer,
its use may still be improved. The present study shows
that tamoxifen metabolism may predict breast cancer out-
come by measuring serum concentrations of active tam-
oxifen metabolites. Our results imply that patients with
serum Z-endoxifen levels lower than 9.00 nM or Z-
4OHtam levels lower than 3.26 nM have poorer long-
term BCSS and OS compared to patient with levels above
these thresholds. The results may translate into clinical
practice by means of therapeutic drug monitoring, which
represents a direct and applicable method to identify
breast cancer patients with poor tamoxifen metabolism
regardless of genotype and inhibiting drug interactions on
the CYP enzymes [35]. Dose adjustment or a switch to an
alternative endocrine treatment could avoid under-
treatment of such patients [36]. Our findings need to be
verified in larger studies, preferable in randomized trials
with a long follow-up time.
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